Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases... Show more
Industry Biotechnology
A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.
| Ticker / NAME | Correlation To GYRE | 1D Price Change % | ||
|---|---|---|---|---|
| GYRE | 100% | +0.27% | ||
| SPRC - GYRE | 38% Loosely correlated | -3.34% | ||
| EDIT - GYRE | 35% Loosely correlated | -6.18% | ||
| TRDA - GYRE | 35% Loosely correlated | -0.96% | ||
| ABSI - GYRE | 35% Loosely correlated | -5.85% | ||
| NKTX - GYRE | 35% Loosely correlated | -3.51% | ||
More | ||||
GYRE's Aroon Indicator triggered a bullish signal on August 31, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 162 similar instances where the Aroon Indicator showed a similar pattern. In 146 of the 162 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on September 08, 2026. You may want to consider a long position or call options on GYRE as a result. In 81 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for GYRE just turned positive on September 17, 2026. Looking at past instances where GYRE's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
GYRE moved above its 50-day moving average on September 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 213 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The 10-day RSI Indicator for GYRE moved out of overbought territory on September 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 26 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
GYRE broke above its upper Bollinger Band on September 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. GYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.220) is normal, around the industry mean (26.453). GYRE's P/E Ratio (390.000) is considerably higher than the industry average of (42.231). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.058). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (438.009).